Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers.

By leveraging nearly a decade of infrastructure investment to drive radical affordability, Hims & Hers is making personalized care more accessible than ever. Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month*.

The new Compounded Semaglutide Pill is formulated to protect the active ingredient during digestion and to support absorption. This innovative delivery method empowers providers to tailor treatments specifically for patients averse to needles or who are looking to help balance side effects.

"We have spent years building the infrastructure required to put the power of choice back into the hands of the individual, and we are committed to ensuring providers can always make the best clinical decision for their patients with an array of safe options to help find care that fits their lifestyle,” said Andrew Dudum, co-founder and CEO of Hims & Hers. "We’re excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere.”

"Our priority is giving providers the most robust toolkit possible to individualize care," said Dr. Craig Primack MD, Head of Weight Loss at Hims & Hers. "Whether a patient needs a specific dosage adjustment or prefers a Compounded Semaglutide Pill over an injection, our platform now supports a deeper level of personalization. That means customers receive weight loss treatment plans curated for their unique needs, helping them achieve holistic health benefits like better sleep, increased energy, and improved metabolism."

Hims & Hers believes the best outcomes start with choice for both providers and customers. Every treatment plan is guided by the patient’s needs and the experienced, clinical judgment of licensed providers. The platform is growing access to a wide range of weight loss treatment options, including branded, generic, and compounded medications, alongside access to 24/7 care team and educational support across nutrition, mental health, and physical wellness.

In 2025, Hims & Hers doubled its facility footprint to over one million square feet, integrating advanced pharmacy capabilities, lab testing, and R&D space. This scale allows the platform to provide clinicians with the tools they need to individualize care at a level previously unavailable at this price point.

Hims & Hers adheres to all applicable federal and state regulatory standards for compounding. All active pharmaceutical ingredients (APIs) in compounded treatments are sourced exclusively from FDA-registered facilities, ensuring quality and safety remain the foundation of every prescription.

*Introductory pricing available to new, qualifying weight loss customers only. From $49 for the first month with a 5-month plan; remaining months at the standard $99 monthly price, paid upfront. Pricing varies by plan. Standard pricing applies after the intro period. Terms apply.

**Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Available as part of a holistic weight loss treatment plan if prescribed by a provider after an online consultation. This compounded product uses a different formulation and delivery system than FDA-approved oral semaglutide.

Wegovy® is not compounded. Wegovy® is available as an injectable and oral pill and is FDA approved for weight loss. Wegovy® is a registered trademark of Novo Nordisk A/S. Hims, Inc. is not affiliated or endorsed by Novo Nordisk A/S.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “step,” “outlook,” “opportunity,” “project,” "“confidence,” “foundation,” “groundwork,” “optimistic,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding expanding customer choice, including with respect to branded GLP-1 offerings. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, failure of our offering to perform as expected; the timing or feasibility of potential future collaborations or expanded access to branded treatment options; changes in healthcare, consumer protection or privacy laws; competitive product launches; higher than anticipated launch or marketing costs; shifts in consumer spending or behavior; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of February 5, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

Press Contact
Jake Martin
press@forhims.com